title: Outcome of patients with unfavorable optimally cytoreduced ovarian cancer treated with chemotherapy and whole abdominal radiation.
abstract: There is a subgroup of patients with Stage II or III ovarian cancer whose survival is poor despite optimal cytoreduction of tumor and abdominopelvic radiation. This study examined whether the survival of these patients, who have tumor with unfavorable histopathological characteristics and/or small residual disease, could be improved by giving chemotherapy before radiation. Forty-four out of fifty-one eligible patients, seen between 1981 and 1985, with Stage II or III disease were entered into the study. Following six courses of cisplatin-based chemotherapy, 33 (75%) received abdominopelvic radiotherapy. Survival was compared to that of 48 eligible matched control patients, treated with radiation between 1978 and 1981. The median follow-up is 6.6 years. The median survival was extended from 2.4 to 5.7 years (P = 0.13), and 42.6% of patients receiving combined therapy were free of relapse at 5 years, compared to 21.6% (P = 0.03) in the historical control group, treated with abdominopelvic irradiation alone. Only 2 of 44 patients in the combined group required surgery for bowel obstruction, as did 1 of 48 in the control group. Tolerance and toxicity of the combined approach were acceptable. Although we cannot be certain that the entire benefit we observed was not attributable to the chemotherapy alone, there is evidence that the radiotherapy may have been additive. Chemotherapy followed by abdominopelvic radiotherapy seems a reasonable management policy in these patients.
authors.affiliation: Department of Medicine, Princess Margaret Hospital, Toronto, Ontario, Canada.
authors.forename: J A
authors.initials: JA
authors.lastname: Ledermann
authors.forename: A J
authors.initials: AJ
authors.lastname: Dembo
authors.forename: J F
authors.initials: JF
authors.lastname: Sturgeon
authors.forename: S
authors.initials: S
authors.lastname: Fine
authors.forename: R S
authors.initials: RS
authors.lastname: Bush
authors.forename: A W
authors.initials: AW
authors.lastname: Fyles
authors.forename: J F
authors.initials: JF
authors.lastname: Pringle
authors.forename: G A
authors.initials: GA
authors.lastname: Rawlings
authors.forename: G M
authors.initials: GM
authors.lastname: Thomas
authors.forename: J
authors.initials: J
authors.lastname: Simm
mesh_terms: D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D009364:Neoplasm Recurrence, Local; D009367:Neoplasm Staging; D010051:Ovarian Neoplasms / Q000401:mortality / Q000473:pathology / Q000628:therapy*; D011182:Postoperative Care; D011379:Prognosis; D011879:Radiotherapy Dosage